Breast cancer is a common disease for woman in worldwide. It cause for 16% of all female cancers Breast cancer rates are much higher in developed nations compared to developing ones.
Scientists from allover the world have been trying to discover a drug to cure breast cancer for along time. Now a new drug called ‘Tucatinib’ shows a great promise to cure breast cancer for women worldwide.
The study team is reporting clinical activity with the investigational oral compound tucatinib, used as part of combination therapy in patients with advanced breast cancer and skin metastases.
The new findings, from a small group of patients enrolled in a Phase Ib study, we represented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark.
The leader of the research Dr. Alison Conlin, a medical oncologist at Providence Cancer Center in Portland, OR, and colleagues released outcomes in eight women with human epidermal growth factor receptor-positive (HER2-positive) metastases to the skin, who were treated with the maximum tolerated dose of tucatinib combined with capecitabine and/or traumatize.
Tucatinib- also called ONT-380 - is a potent selective small molecule inhibitor of HER2.
The cutaneous metastases have been estimated to occur in approximately 25 percent of women with metastatic breast cancer and are often the first sign of extranodal metastatic disease. Their frequency is thought to be even higher in the presence of HER2 over expression.
The researchers have hypothesized that skin, like the central nervous system, may represent a sanctuary site for breast cancer cells during treatment withanti-HER2 antibodies.
It is found that skin metastases are a difficult site of disease control in women with HER2-overexpressing metatastic breast cancer. At present, there is no approved therapy for such lesions in these patients.
Skin lesions is lessened by Tucatinib
The new research participants had undergone prior treatment with trastuzumab,taxane, and trastuzumab emtansine. Most of them had also been treated with lapatinib, pertuzumab, and/or radiation to the chest wall/skin. Patients had received a median of six prior lines of therapy.
It was found that one patient had a complete response after tucatinib treatment, defined as a disappearance of all skin lesions. Three patients had partial responses, defined as a greater than 30percent reduction in the sum of diameters of all target skin lesions from baseline. The remaining four patients had stable disease.
"We observed great responses in the skin in our patients with metastatic breast cancer and skin metastases who were treated with tucatinib and either trastuzumab, capecitabine, or all three drugs in combination.
The medical science describes that the skin is a very morbid and difficult area of disease for women with metastatic breast cancer with a resulting profound impairment in their quality of life, and therefore response in this difficult area to treat is needed, “says Dr. Alison Conlin
The new study on breast cancer was conducted by teams from multiples sites in the United States, including the Providence Cancer Center in Portland, and the University of Colorado in Aurora, and the MD Anderson Cancer Center in Houston.